Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
As of today, Johnson & Johnson(JNJ) shares are valued at $205.90. The company's market cap stands at 495.45B, with a P/E ratio of 20.02 and a dividend yield of 2.5%.
On 2026-01-08, Johnson & Johnson(JNJ) stock traded between a low of $204.97 and a high of $208.91. Shares are currently priced at $205.90, which is +0.5% above the low and -1.4% below the high.
Johnson & Johnson(JNJ) shares are trading with a volume of 6.56M, against a daily average of 5.56M.
During the past year, Johnson & Johnson(JNJ) stock moved between $140.68 at its lowest and $215.19 at its peak.
During the past year, Johnson & Johnson(JNJ) stock moved between $140.68 at its lowest and $215.19 at its peak.
JNJ News
Johnson & Johnson said that, as part of its previously announced $55B investment to support U.S. manufacturing, it is announcing two new U.S. manufacturing faci...
Johnson & Johnson announced a voluntary agreement with the Trump Administration to “improve access to medicines and lower costs for millions of American patient...
Lexeo Therapeutics (LXEO) announced a research collaboration with Johnson & Johnson (JNJ) to investigate localized cardiac delivery of gene therapy. The collabo...
Analyst ratings
56%
of 27 ratingsMore JNJ News
In early January 2026, Johnson & Johnson reported encouraging Phase 2b results for its lupus drug nipocalimab and submitted its OTTAVA robotic surgical system t...
Johnson & Johnson JNJ announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for treating adult patients with systemic...
Johnson & Johnson announced that the company has submitted the Ottava Robotic Surgical System to the FDA in an application for De Novo classification. Leveragin...
Wondering if Johnson & Johnson is still a solid price for a long-term holding or if the recent run has moved it too far, too fast? This article focuses squarely...
It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year's. Do you have some idle cash you...
Technology Alumis Stock Catapults More Than 100% As Biotech Takes On J&J, Protagonist In Psoriasis Licensing Biotech stock Alumis (ALMS) catapulted on Tuesday a...
Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called systemic lupus erythematosus, reached...
